Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Insider Sells 11,095 Shares of Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) insider James Woodruff Lillie sold 11,095 shares of the stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $28.20, for a total value of $312,879.00. Following the sale, the insider owned 268,261 shares of the company’s stock, valued at approximately $7,564,960.20. This represents a 3.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Woodruff Lillie also recently made the following trade(s):

• On Wednesday, May 6th, James Woodruff Lillie sold 24,811 shares of Maplight Therapeutics stock. The stock was sold at an average price of $28.76, for a total value of $713,564.36.
• On Monday, May 4th, James Woodruff Lillie sold 15,801 shares of Maplight Therapeutics stock. The shares were sold at an average price of $27.96, for a total value of $441,795.96.

Maplight Therapeutics Price Performance

Maplight Therapeutics stock traded up $1.12 during midday trading on Wednesday, reaching $29.04. The company’s stock had a trading volume of 267,979 shares, compared to its average volume of 342,018. The firm has a market capitalization of $1.24 billion and a PE ratio of -0.73. The stock’s 50-day simple moving average is $22.60. Maplight Therapeutics, Inc. has a 52-week low of $12.24 and a 52-week high of $33.28.

Maplight Therapeutics (NASDAQ:MPLT) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($2.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($1.42). Equities research analysts predict that Maplight Therapeutics, Inc. will post -3.96 earnings per share for the current year.

More Maplight Therapeutics News

Here are the key news stories impacting Maplight Therapeutics this week:

• Positive Sentiment: Needham reaffirmed its “Buy” rating on MPLT, signaling continued analyst conviction that the shares have upside. Needham Reaffirms Buy
• Positive Sentiment: HC Wainwright initiated/updated coverage with a “Buy” rating and a $45 price target (roughly mid‑50% upside from recent levels), which can attract buyers and support the rally. Many outlets reported the new coverage and target. HC Wainwright Coverage & Target
• Neutral Sentiment: Morningstar and market quote pages show current trading context (price, volume, 50‑day moving average) that traders use to gauge technical support/resistance. Use these pages for up‑to‑date quotes. Morningstar Quote
• Negative Sentiment: HC Wainwright’s detailed forecasts also project larger net losses over 2026–2027 (FY2026 EPS ~ -$4.34; FY2027 EPS ~ -$5.25) and quarterly losses through 2027 — data that underscores continued cash‑burn and execution risk for a clinical‑stage biotech. This raises downside risk if clinical or financing progress stalls. Analyst Estimates
• Negative Sentiment: Recent reported results included a sizable Q1 EPS miss (reported -$2.47 vs. consensus -$1.05), which remains a reminder of earnings volatility and could pressure sentiment if follow‑up data or guidance are weak. Recent Earnings Miss

Hedge Funds Weigh In On Maplight Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp grew its holdings in Maplight Therapeutics by 10.1% during the first quarter. Bank of New York Mellon Corp now owns 39,465 shares of the company’s stock worth $802,000 after acquiring an additional 3,608 shares during the period. T. Rowe Price Investment Management Inc. acquired a new position in Maplight Therapeutics in the fourth quarter valued at approximately $49,168,000. Invesco Ltd. purchased a new stake in Maplight Therapeutics in the 4th quarter worth approximately $228,000. Vestal Point Capital LP purchased a new stake in Maplight Therapeutics in the 4th quarter worth approximately $6,763,000. Finally, Tudor Investment Corp ET AL purchased a new stake in Maplight Therapeutics in the 4th quarter worth approximately $840,000.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on MPLT. HC Wainwright initiated coverage on shares of Maplight Therapeutics in a research note on Monday. They set a “buy” rating and a $45.00 price objective for the company. Canaccord Genuity Group assumed coverage on Maplight Therapeutics in a research note on Thursday, March 19th. They issued a “buy” rating and a $35.00 target price for the company. Wall Street Zen cut Maplight Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. TD Cowen initiated coverage on Maplight Therapeutics in a research note on Tuesday, April 7th. They set a “buy” rating on the stock. Finally, Weiss Ratings initiated coverage on Maplight Therapeutics in a research note on Thursday, January 22nd. They issued a “sell (e)” rating for the company. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $34.43.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.